Tag: Bristol-Myers Squibb
Bristol Myers Squibb announces success of KRAZATI in Phase 3 KRYSTAL-12 study
Bristol Myers Squibb (NYSE: BMY) has reached a pivotal milestone in the treatment of non-small cell lung cancer (NSCLC) with its announcement regarding the KRYSTAL-12 ... Read More
Bristol Myers Squibb and 2seventy bio’s Abecma gets positive FDA committee vote for multiple myeloma
In a significant development in the healthcare industry, Bristol Myers Squibb (NYSE: BMY) and 2seventy bio, Inc. (Nasdaq: TSVT) have announced a favorable vote by ... Read More
Bristol Myers Squibb announces Opdivo FDA approval for urothelial carcinoma
In a significant stride toward enhancing bladder cancer treatment, Bristol Myers Squibb (NYSE: BMY) announced the U.S. Food and Drug Administration (FDA) approval of Opdivo ... Read More
Bristol Myers Squibb’s subcutaneous nivolumab shows promise in Phase 3 RCC trial
Bristol Myers Squibb (NYSE: BMY) has announced results from its Phase 3 CheckMate -67T trial, which could revolutionize treatment for patients with advanced or metastatic ... Read More
Bristol Myers Squibb CAR T cell therapy Breyanzi shows promising outcomes in clinical trials
Bristol Myers Squibb (NYSE: BMY) has unveiled primary analysis results from the TRANSCEND FL clinical trial at the 2023 American Society of Hematology (ASH) Annual ... Read More
Bristol Myers Squibb to acquire Mirati Therapeutics in $4.8bn deal
Bristol Myers Squibb (NYSE: BMY) is set to acquire Mirati Therapeutics, Inc. (NASDAQ: MRTX) at $58.00 per share in a cash deal valued at $4.8 ... Read More
Bristol Myers’ BMS-986278 yields promising results in slowing pulmonary fibrosis progression in Phase 2 trial
Bristol Myers Squibb (NYSE: BMY) disclosed a pivotal Phase 2 study highlighting that BMS-986278, an investigational oral LPA1 antagonist, reduces the rate of lung function ... Read More
MEDiC Life Sciences, Bristol Myers Squibb to advance discovery of tumor targets
MEDiC Life Sciences, a biotech startup based in Silicon Valley, has announced a research collaboration with pharmaceutical giant Bristol Myers Squibb to advance the discovery ... Read More
BMS-986278 succeeds in phase 2 idiopathic pulmonary fibrosis trial, says Bristol Myers Squibb
Bristol Myers Squibb (BMS) said that BMS-986278 has succeeded in lowering the rate of lung function decline in idiopathic pulmonary fibrosis patients in a phase ... Read More
NATCO Pharma launches lenalidomide 2.5mg and 20mg in US
NATCO Pharma said that it has launched additional strengths for the generic version of Revlimid (lenalidomide capsules), in the strengths of 2.5mg and 20mg in ... Read More